Mutation profile differences in younger and older patients with advanced breast cancer using circulating tumor DNA (ctDNA)

[1]  Nora S. Sanchez,et al.  Identification of Actionable Genomic Alterations Using Circulating Cell-Free DNA. , 2019, JCO precision oncology.

[2]  S. Neuhausen,et al.  Prevalence and characteristics of likely-somatic variants in cancer susceptibility genes among individuals who had hereditary pan-cancer panel testing. , 2019, Cancer genetics.

[3]  H. Rugo,et al.  Alpelisib for PIK3CA‐Mutated, Hormone Receptor–Positive Advanced Breast Cancer , 2019, The New England journal of medicine.

[4]  A. Picornell,et al.  Concordance of Genomic Variants in Matched Primary Breast Cancer, Metastatic Tumor, and Circulating Tumor DNA: The MIRROR Study. , 2019, JCO precision oncology.

[5]  D. Tripathy,et al.  Progression-free survival (PFS) and toxicities of palbociclib in a geriatric population , 2019, Breast Cancer Research and Treatment.

[6]  P. Bernard,et al.  Differences in molecular features of triple‐negative breast cancers based on the age at diagnosis , 2018, Cancer.

[7]  Lu-ying Tang,et al.  Molecular features in young vs elderly breast cancer patients and the impacts on survival disparities by age at diagnosis , 2018, Cancer medicine.

[8]  C. Paweletz,et al.  Validation of a Plasma-Based Comprehensive Cancer Genotyping Assay Utilizing Orthogonal Tissue- and Plasma-Based Methodologies , 2018, Clinical Cancer Research.

[9]  G. Ciliberto,et al.  Tearing down the walls: FDA approves next generation sequencing (NGS) assays for actionable cancer genomic aberrations , 2018, Journal of experimental & clinical cancer research : CR.

[10]  J. Subramanian,et al.  Correlation of Somatic Genomic Alterations Between Tissue Genomics and ctDNA Employing Next-Generation Sequencing: Analysis of Lung and Gastrointestinal Cancers , 2018, Molecular Cancer Therapeutics.

[11]  L. Saal,et al.  Tumor PIK3CA Genotype and Prognosis in Early-Stage Breast Cancer: A Pooled Analysis of Individual Patient Data. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  G. Hortobagyi,et al.  Characterization of bone only metastasis patients with respect to tumor subtypes , 2018, npj Breast Cancer.

[13]  S. Mortimer,et al.  The Landscape of Actionable Genomic Alterations in Cell-Free Circulating Tumor DNA from 21,807 Advanced Cancer Patients , 2017, Clinical Cancer Research.

[14]  C. Paweletz,et al.  Discrimination of Germline EGFR T790M Mutations in Plasma Cell-Free DNA Allows Study of Prevalence Across 31,414 Cancer Patients , 2017, Clinical Cancer Research.

[15]  Eduardo Vilar,et al.  Clinical utility of circulating cell-free DNA in advanced colorectal cancer , 2017, PloS one.

[16]  Kari Stefansson,et al.  Clonal hematopoiesis, with and without candidate driver mutations, is common in the elderly. , 2017, Blood.

[17]  K. Hess,et al.  Initiative for Molecular Profiling and Advanced Cancer Therapy (IMPACT): An MD Anderson Precision Medicine Study. , 2017, JCO precision oncology.

[18]  P. Stephens,et al.  BRAF: An emerging target for triple-negative breast cancer. , 2017 .

[19]  Edward S. Kim,et al.  Molecular profiling comparison of breast cancer subtypes in young women and older women. , 2017 .

[20]  Donavan T. Cheng,et al.  Mutational Landscape of Metastatic Cancer Revealed from Prospective Clinical Sequencing of 10,000 Patients , 2017, Nature Medicine.

[21]  E. Saad,et al.  Clinical Implications of ESR1 Mutations in Hormone Receptor-Positive Advanced Breast Cancer , 2017, Front. Oncol..

[22]  James D. Brenton,et al.  Liquid biopsies come of age: towards implementation of circulating tumour DNA , 2017, Nature Reviews Cancer.

[23]  B. Reva,et al.  Genomic Analysis of Uterine Lavage Fluid Detects Early Endometrial Cancers and Reveals a Prevalent Landscape of Driver Mutations in Women without Histopathologic Evidence of Cancer: A Prospective Cross-Sectional Study , 2016, PLoS medicine.

[24]  Peter Horak,et al.  Integrating next-generation sequencing into clinical oncology: strategies, promises and pitfalls , 2016, ESMO Open.

[25]  B. Das,et al.  Molecular evaluation of PIK3CA gene mutation in breast cancer: determination of frequency, distribution pattern and its association with clinicopathological findings in Indian patients , 2016, Medical Oncology.

[26]  B. Kermani,et al.  Analytical and Clinical Validation of a Digital Sequencing Panel for Quantitative, Highly Accurate Evaluation of Cell-Free Circulating Tumor DNA , 2015, PloS one.

[27]  C. Sotiriou,et al.  Genomic aberrations in young and elderly breast cancer patients , 2015, BMC Medicine.

[28]  C. Kelly,et al.  Targeted therapy in older patients with solid tumors. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  Luca Fumagalli,et al.  Biopsy confirmation of metastatic sites in breast cancer patients: clinical impact and future perspectives , 2014, Breast Cancer Research.

[30]  J. Merlin,et al.  Analysis of PIK3CA exon 9 and 20 mutations in breast cancers using PCR-HRM and PCR-ARMS: correlation with clinicopathological criteria. , 2013, Oncology reports.

[31]  Irmtraud M. Meyer,et al.  The clonal and mutational evolution spectrum of primary triple-negative breast cancers , 2012, Nature.

[32]  D. Goldberg,et al.  Disparate inclusion of older adults in clinical trials: priorities and opportunities for policy and practice change. , 2010, American journal of public health.

[33]  W. Gerald,et al.  PIK3CA Mutation Associates with Improved Outcome in Breast Cancer , 2009, Clinical Cancer Research.

[34]  G. Hortobagyi,et al.  PIK3CA-activating mutations and chemotherapy sensitivity in stage II–III breast cancer , 2008, Breast Cancer Research.

[35]  C. Tzen,et al.  PIK3CA Exon 20 Mutation is Independently Associated with a Poor Prognosis in Breast Cancer Patients , 2008, Annals of Surgical Oncology.

[36]  F. Real,et al.  Oncogenic PIK3CA mutations occur in epidermal nevi and seborrheic keratoses with a characteristic mutation pattern , 2007, Proceedings of the National Academy of Sciences.

[37]  Harlan M Krumholz,et al.  Participation in cancer clinical trials: race-, sex-, and age-based disparities. , 2004, JAMA.

[38]  V. Danilenko,et al.  Supplemental Data , 2012 .